LAVA Therapeutics’ (LVTX) Neutral Rating Reiterated at HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reiterated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $1.50 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 20.00% from the company’s current price.

LVTX has been the topic of a number of other reports. Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Stock Performance

Shares of NASDAQ LVTX opened at $1.25 on Monday. The business’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.36. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.57. The firm has a market cap of $32.87 million, a price-to-earnings ratio of -1.21 and a beta of 0.48.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Friday, March 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.18. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.40 million. As a group, equities research analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Institutional Investors Weigh In On LAVA Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics during the 3rd quarter worth about $32,000. BNP Paribas Financial Markets acquired a new position in LAVA Therapeutics in the fourth quarter valued at about $40,000. Finally, Sanofi bought a new stake in LAVA Therapeutics during the fourth quarter worth about $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.